Digital Age: Otsuka Sets Sights On Abilify Combo Tablet With Sensor
This article was originally published in The Pink Sheet Daily
Executive Summary
First-of-its-kind NDA is for a combination product of Abilify embedded with an ingestible sensor to measure adherence and physiologic response. Otsuka sees opportunities to extend brand facing generic competition and for combo approach with future medicines too.
You may also be interested in...
First ‘Digital Medicine’ Approved, Slow Rollout Planned
FDA has approved Abilify MyCite, a treatment for some psychiatric conditions that integrates a drug with a sensor that records when the medication is taken. The goal is to track medication compliance. It is an important regulatory milestone for the nascent field of digital medicine, but many questions about the market remain.
FDA Approves First Digital Pill: Otsuka/Proteus' Abilify MyCite
Otsuka plans a slow, measured launch of Abilify MyCite, developed with Proteus Health. The product includes an ingested sensor that sends a signal to a wearable patch and an app that tracks ingestion, activity and mood to potentially improve management of psychiatric care.
Long-Acting Atypical Antipsychotic Market Snapshot: A One-Company Market Begins To Diversify
Otsuka and Lundbeck’s newly approved long-acting antipsychotic Abilify Maintena enters a sub-sector of the anti-psychotic market dominated by Johnson & Johnson for the last decade, but the new competitor may be able to gain ground by helping to grow the patient population.